NordMedica A/S has been acquired by Eurocept B.V.
The Dutch pharmaceutical company Eurocept B.V. has acquired 100% of the share capital in the Danish specialty pharmaceutical company NordMedica A/S for an undisclosed consideration.
NordMedica A/S was founded in 2003 as a privately held specialty pharmaceutical company focused on the commercialization and marketing of niche pharmaceutical products. The company holds the rights to an oncology product under the brand names Amekrin®, Amsidine® and Amsidyl® in more than 25 countries. The product is based on a chemotherapy drug for the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphatic Leukemia (ALL). All other assets and liabilities together with all employees were transferred to NordMedica International before the transaction.
Eurocept is a rapidly growing company active in the pharmaceutical and homecare market in the Benelux countries. Eurocept offers products and services that answer to pharmaceutical, technological and nursing needs in medical care as well as a unique combination of medical technology and distribution in the therapeutic areas of anesthesia, oncology, pediatrics, psychiatry, immunology, ADHD and urology.
Oaklins' team in Denmark acted as financial and strategic advisor to the seller in this transaction.
Talk to the deal team
Related deals
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn morePhen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Learn moreMedis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
Learn more